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Leishmaniasis is caused by different species of the protozoa, Leishmania, and frequently
found in South-Western Asia, Eastern Africa, Brazil, and Mediterranean countries. Leish-
mania are transmitted to humans by the bite of sandflies. After weeks to months, unspe-
cific symptoms may occur, accompanied by more specific findings like pancytopenia and
organomegaly. We report two children with pancytopenia and hepato-/splenomegaly: a
1-year-old boy was first diagnosed with an Adenovirus-infection, accompanied by fever,
pancytopenia, and hepatosplenomegaly who had spent his summer vacation in Spain
and a 3-year-old boy of Macedonian origin who was first diagnosed with a Parvovirus
B19-infection again accompanied by splenomegaly and pancytopenia. In both children,
leukemia was excluded by an initial bone marrow puncture. As fever was still persistent
weeks after the children’s first hospital stay, both children received antibiotics empirically
without sustainable effect. While different autoantibodies were present in both children, an
immunosuppressive therapy was initiated in the younger boy without therapeutic success.
A second bone marrow puncture was performed and Leishmania were finally detected
morphologically and proven serologically. After weight-adjusted treatment with liposomal
Amphotericin B for 10 days, both children recovered completely without relapse. Aim
of this report is to broaden the spectrum of differential diagnoses in children with
pancytopenia, splenomegaly, and fever to visceral leishmaniasis particularly when travel
history is positive for the Mediterranean area. The infection may mimic more common
diseases, such as leukemia, viral infections, or autoimmune diseases, because polyclonal
B cell activation and other mechanisms may lead to multiple positive serologic tests. Both
cases illustrate typical pitfalls and shall encourage taking Leishmaniasis into diagnostic
consideration.
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Introduction
We would like to discuss two cases where children presented with fever, pancytopenia, and
hepatosplenomegaly with a focus on infectious, autoimmune, and malignant differential diagnoses.
Case 1
A 1-year-old boy (patient A) was referred to our hospital because of a persistent pancytopenia. He
was treated initially because of anAdenovirus infection accompanied by recurrent fever, rhinitis, and
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FIGURE 1 | Photomicroscopy of the first bone marrow puncture in
patient A (Pappenheim’s staining, 100 magnification): Leishmania
are difficult to detect and subtle (arrowhead indicates Leishmania).
FIGURE 2 | Photomicroscopy of the first bone marrow puncture in
patient A (Pappenheim’s staining, 100 magnification): Leishmania
can also be seen intracellular in the first smear (arrowheads indicate
Leishmania).
cough. Apart from hepatosplenomegaly, the clinical examina-
tion at our hospital was unremarkable; the boy was in satisfying
general condition. Laboratory findings encompassed a positive
Adenovirus PCR in peripheral blood, bone marrow, and feces,
and a conspicuous complete blood count indicating leukopenia,
thrombocytopenia, anemia as well as an elevated C-reactive pro-
tein (CrP) level at first. To exclude acute leukemia, a bonemarrow
puncture was performed. Leishmania were already visible in the
first blood smears but were not recognized as Leishmania at that
point. Hence, Leishmaniasis was not taken into diagnostic consid-
eration at first and the bone marrow therefore falsely interpreted
as being normal (Figures 1 and 2). A positive direct Coombs
test and antibodies against neutrophil granulocytes as well as
against platelets were detected later on (Table 1). Despite the
positive direct Coombs test, no further signs of hemolysis could
be detected. In the absence of other explanations, pancytopenia
was interpreted as most likely being virus-associated. The boy
was discharged in stable condition. Yet, even weeks after the
first hospital stay, fever, pancytopenia, and hepatosplenomegaly
were still present. Although no infectious focus was found, an
empirical antibiotic therapy was started without sustainable suc-
cess. Because of the presence of antibodies against neutrophils,
platelets, and a positive direct Coombs test, Evans syndrome
was considered in the further course, and an immunosuppres-
sive therapy with prednisolone and mycophenolate mofetil was
initiated. Despite a slight increase in leukocytes and hemoglobin,
pancytopenia, recurrent fever, and hepatosplenomegaly were still
persistent 3months after the child’s first hospital admission. Due
to the unspecific laboratory findings and sustained pancytopenia,
a second bone marrow puncture was performed. Here, parasites
suspicious for Leishmania were finally detected morphologically
and later on Leishmania species of the L. donovani complex
(L. donovani, L. infantum, and L. chagasi) were proven sero-
logically (Figures 3 and 4). Six months before the first symp-
toms had occurred, the boy had spent the summer vacation in
Spain together with his parents and his twin brother. An intra-
venous therapy with liposomal Amphotericin B (2.8mg/kg/day)
was administered for 10 days. Following this treatment, the boy
recovered completely and showed no relapse so far. The blood
count fully recovered almost 2months after the end of the
therapy; hepatosplenomegaly resolved 9months after the end
of therapy.
The boy’s twin brother, who had been on the same vacation and
had spent the entire time close to his brother, showed no symp-
toms or blood count irregularities at any time and no Leishmania
antibodies were detected serologically.
Case 2
A 3-year-old boy of Macedonian origin (patient B) was referred
to our hospital due to a palpable resistance in the left upper
abdomen and a microcytic anemia. On clinical examination, an
isolated splenomegaly was found (Table 1). No further clinical
findings could be detected. In the laboratory results, slightly
lowered platelets and erythrocytes were present while the white
blood counts remained normal at the beginning, yet deterio-
rated in the course of the disease resulting in pancytopenia.
A positive direct Coombs test also without signs of hemoly-
sis could be detected here. Viral serology was positive for Par-
vovirus B19 (Table 1). Consecutively, a bone marrow puncture
was performed without pathological findings. The Parvovirus
B19 infection was considered the most likely reason of pancy-
topenia. Four weeks after the first hospital admission, the boy
returned with recurrent fever and sweating. Because of high
fever, an empirical antibiotic therapy was performed yet with-
out success. Pancytopenia and splenomegaly were still persistent
and progressive, accompanied by hepatomegaly. Conspicuous
laboratory findings were a positive direct Coombs test as well
as a positive Hanta-Virus IgM. A second bone marrow punc-
ture was performed and now parasites suspicious for Leishma-
nia could be detected and later on species of the L. donovani
complex were confirmed serologically. Treatment with liposo-
mal Amphotericin B (2.7mg/kg/day) was performed for 10 days
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TABLE 1 | Clinical and laboratory findings at admission/during the first stay.
Patient A (1-year-old boy) Patient B (3-year-old boy)
Clinical findings at admission Hepatosplenomegaly, recurrent fever Hepatosplenomegaly, recurrent fever, sweats
Measurements in the abdominal
ultrasound at admission/maximum sizes
(measured in the anterior axillary line)
Liver 10.9 cm/11.5 cm (upper normal value: 8.9 cm)
Spleen 10.2 cm/12.1 cm (upper normal value: 5.2 cm)
Liver 9.8 cm/11.5 cm (upper normal value: 10.72 cm)
Spleen 11.2/14.9 cm (upper normal value: 6.74 cm)
Blood count at admission Leukocytes 5500/µl (6000–18000) Leukocytes 6600/µl (5000–17,000)
Erythrocytes 3.3Mio/µl (3.8–5.3) Erythrocytes 3.29Mio/µl (4.2–5.5)
Platelets 17,000/µl (130,000–170,000) Platelets 127,000/µl (130,000–170,000)
Hemoglobin 7.0 g/dl (10.2–13.4) Hemoglobin 7.7 g/dl (11.1–13.9)
Hematocrit 23.6% (31–40) Hematocrit 23.0% (33–41)
Mean corpuscular volume 72.4 fl (70–86) Mean corpuscular volume 69.9 fl (75–87)
Mean corpuscular hemoglobin 21.5 pg (23–31) Mean corpuscular hemoglobin 23.4 pg (20–32)
Red cell distribution width 18.1% (11.6–14.6) Red cell distribution width 14.8% (11.6–14.6)
CrP 7.1mg/dl (<0.5) CrP 2.7mg/dl (<0.5)
Reticulocyte index 6.6% (0.5–2) Reticulocyte index 5.4% (0.5–2)
Reticulocytes 238,000/µl (22,000–112,000) (4weeks
after first admission)
Reticulocytes 176,000/µl (22,000–112,000)
Virology/microbiology at admission Anti-HHV6-IgG positive
Anti-HHV6-IgM unspecific (blood)
Adenovirus-DNA-PCR positive [respiratory swab
(12,100Copies/ml), bone marrow
(15,800Copies/µg-DNA), and blood
(10,700Copies/µg-DNA)]
Parvovirus B19 IgG+ IgM positive
Parvovirus B19-PCR positive (255,623 IU/ml)
Anti-CMV-IgG positive
Anti-HHV6-IgG positive
Anti-HHV6-IgM unspecific (blood)
Autoantibodies Positive direct Coombs test Positive direct Coombs test
Antibodies against neutrophils
Antibodies against platelets
Immunoglobulin IgG 1890mg/dl (232–1411) IgG 2670mg/dl (500–1300)
IgA 111mg/dl (<83) IgA 97mg/dl (40–180)
IgM 286mg/dl (<145) IgM 196mg/dl (40–80)
and the boy recovered without relapse. Three months after the
initial admission, Hanta-Virus IgM as well as Hanta-Virus IgG
was negative.
Background
Visceral leishmaniasis is an infection caused by different species of
the protozoa Leishmania. Leishmania are transmitted to humans
by the bite of sandflies. After weeks to months, unspecific symp-
toms, such as fever, loss of appetite, weight loss, and lym-
phadenopathy, may occur, often accompanied by more specific
findings, such as pancytopenia and hepatosplenomegaly (1–3).
In addition, different autoantibodies against cellular and humoral
components may occur (4, 5). In the described cases here, pan-
cytopenia was the most striking finding, which lead to different
diagnostic procedures. In children with pancytopenia, first of
all, common bone marrow disease, such as leukemia, have to
be considered. More seldomly, diseases, such as myelodysplas-
tic syndrome or aplastic anemia, are being found. Furthermore,
multiple viral agents, such as EBV, CMV, HIV, and in rare cases
also Rubella, Influenza, Parainfluenza, and Hepatitis A can lead to
pancytopenia. Finally, toxic substances, such as cytostatic drugs,
irradiation, and severe vitamin B 12 deficiency, have to be taken
into consideration when pancytopenia occurs in children. A bone
marrow puncture is needed to clarify further diagnostic and
therapeutic steps.
Leishman andDonovan first described visceral leishmaniasis in
1903. Manifestations of leishmaniasis comprise cutaneous leish-
maniasis, characterized by local cutaneous lesions, mucosal leish-
maniasis, affecting the oral mucosa and the mucosa of the upper
airways, and visceral leishmaniasis with a potentially fatal course if
untreated. Leishmaniasis is a globally distributed disease observed
in more than 80 countries worldwide. Although the majority of
cases occur in countries, such as Bangladesh, Brazil, India, and
Sudan (6), leishmaniasis is also endemic, e.g., in the Mediter-
ranean Area. In this area, Morocco, Italy, Albania, Algeria, and
Spain reported the highest number of cases of visceral leishmani-
asis (7). Thus, visceral leishmaniasis remains no longer a merely
tropical disease, but must be taken into consideration also in
Germany with many travelers returning from the Mediterranean
area every year (8, 9). Once diagnosed, liposomal amphotericin
B is an effective drug with only mild side effects (10, 11). Oral
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FIGURE 3 | Photomicroscopy of the second bone marrow puncture in
patient A (Pappenheim’s staining, magnification 100): numerous
Leishmania species are clearly visible intra- and extracellularly.
FIGURE 4 | Photomicroscopy of the second bone marrow puncture in
patient A (Pappenheim’s staining, magnification 100): numerous
Leishmania species are clearly visible intra- and extracellularly.
miltefosine, an antiprotozoal alkylphosphocholine agent, might
be the first choice in developing countries due to lower costs in
comparison to liposomal Amphotericin B and has been proven to
be effective as well (12).
Discussion
We report and discuss two patients who presented with fever,
pancytopenia, and organomegaly. After initially misleading lab-
oratory results in respect of viral or even autoimmune etiology,
visceral leishmaniasis was finally diagnosed after performing a
second bone marrow examination. A successful antimicrobial
therapy was finally initiated.
In our department of Pediatric Oncology, Hematology, and
Clinical Immunology, a total of two patients were diagnosed with
visceral leishmaniasis in the past 10 years. In comparison, 266
cases of hematologic neoplasias (acute lymphoblastic leukemia,
acute myeloid leukemia, chronic myeloid leukemia, myelodys-
plastic syndrome, juvenile myelomonocytic leukemia) and severe
aplastic anemia were diagnosed in our department between 2005
and 2014, which is an average of 26 per year. Thus, with an average
of 0.2 cases per year, visceral leishmaniasis remains a very rare
disease. Diagnosis of this infection can be very challenging for
several reasons.
Both cases illustrate that the correct diagnosis of leishmaniasis
may be delayed up to months after first symptoms occur. Unspe-
cific autoimmune findings, such as detection of autoantibodies,
may lead to misdiagnosis of an autoimmune disease. Especially in
patient A, the detected antibodies against platelets and neutrophils
as well as the positive direct Coombs test mislead and raised
suspicion for an autoimmune disease.
Also, in the cases presented here, initial bone marrow analyses
failed to detect Leishmania even though retrospectively isolated
parasites where already visible here. Moreover, both patients obvi-
ously suffered from concurrent viral infections. In patient A, pan-
cytopenia was expected to be caused by the Adenovirus infection.
In patient B, a Parvovirus B19-infection was detected. Although
mostly transient aplastic anemia occurs due to a Parvovirus B19-
infection in the bone marrow, persistent pancytopenia and severe
aplastic anemia have also been described for immunocompetent
and immunocompromised patients infected with Parvovirus B19
(13–16). Leishmaniasis may mimic autoimmune cytopenias like
Evans syndrome or be associated with viral infections but it may
also lead to and mimic less frequent diseases, such as macrophage
activation syndrome (MAS) (17, 18) or systemic lupus erythe-
matosus (19). MAS is characterized by T cell and macrophage
activation, leading to cytokine overproduction resulting in inflam-
mation. Due to increased macrophage activation, blood cells may
be phagocytosed consecutively leading to cytopenia (17). In a very
recent study, it has been shown that autophagocytosis may play an
important role in the immune response to Leishmania. Whereas
other infections may trigger macrophage activation and T cell
response, an infection with vital and dead Leishmania at the same
time may induce autophagocytosis in cells infected with dead
Leishmania resulting in a hampered adaptive immune response,
so vital Leishmania will not be killed at all. In cells only infected
with vital Leishmania, the immune response is not hampered
due to the missing induction of autophagocytosis. According to
these study results, an infection solely with vital Leishmania will
not lead to autophagocytosis and the immune response kills the
entered Leishmania (20). Several investigators have revealed the
presence of autoantibodies against cellular and humoral compo-
nents as well as against nuclear antigens (4, 5) in visceral leishma-
niasis. Many different autoantibodies/laboratory values might be
altered, such as antinuclear antibodies (ANA), rheumatic factor,
anti-cardiolipin antibodies, cryoglobulins, Coombs test, hyper-
gammaglobulinemia, anti-smooth muscle antibodies (ASMA),
protoplasmic-staining anti-neutrophil cytoplasmic antibodies (p-
ANCA), anti-extractable nuclear antigens antibodies (anti-ENA),
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anti-myeloperoxidase antibodies (anti-MPO), anti-Smith anti-
bodies (anti-SM), anti-Sjögren’s-syndrome-related antigen A
(anti-SS-A)/anti-Ro antibodies (anti-Ro), anti-SS-B/anti-La, anti-
ribonucleoprotein antibodies (anti-RNP), and decreased C3 and
C4 (4, 5, 21). Liberopoulos et al. showed that all autoimmune
laboratory findings normalized only 3months after therapy (21).
Therefore, it is important to keep in mind that leishmaniasis
might resemble autoimmune diseases in a sense that autoantibod-
ies may be detectable as presented here. The presence of these
unspecific autoantibodies may be explained in part by polyclonal
B-cell-activation, which may lead to hypergammaglobulinemia
(4, 22, 23). Of note, both children in our cases showed ele-
vated immunoglobulin G levels during their first hospital stay.
In patient B, we detected a positive Hanta-Virus IgM beside the
unspecific autoimmune findings, which was negative 3months
after initial admission. The Hanta-Virus IgG has never been pos-
itive. It cannot be excluded that these antibodies were positive
due to polyclonal B-cell activation, but it seems to be more
likely that theHanta-Virus-IgM was positive due to cross-reacting
antibodies.
Our reported cases underline the importance of thorough his-
tory taking regarding past travel history. Especially in Western
countries, it is important to remember that leishmaniasis is not
only a tropical disease but also endemic in some of our favorite
travel destinations in the Mediterranean area (7). A recent multi-
centre study reported at least 10 travelers who visited endemic
areas in Europe between 2000 and 2012 and developed visceral
leishmaniasis. The visited countries were – amongst others –
Spain, Portugal, Greece, andMacedonia (24). Several investigators
have shown that infections acquired in theMediterranean area are
mostly caused by species of the L. donovani complex, especially L.
infantum (24–27). In our reported cases, species of the L. donovani
complex were detected as well. The latest reported outbreaks of
leishmaniasis in Spain (2009, caused by L. infantum) and Italy
(2012) demonstrate that leishmaniasis is a current challenge that
needs to be faced (26, 28).
Therefore, Smith et al. underline the importance of thorough
history taking especially with regard to holidays spent in the
Mediterranean basin as visceral leishmaniasis can no longer be
considered to be an “exotic” disease (29). Leishmaniasis is char-
acterized by a long incubation period of weeks to months, sel-
dom years (30). Thus, due to the long interval between travel
activity and onset of symptoms, important stays abroad may not
be reported in first place. This may add to a delay of the cor-
rect diagnosis (29). In our reported cases, patient A had his last
stay abroad in an endemic region 6months before disease onset
(vacation in Spain), patient B at least 1 year before (vacation in
Macedonia). Although it is often stated that visceral leishmania-
sis affects especially young children, in different studies dealing
with visceral leishmaniasis acquired in Europe, patients affected
seem to be adults. In a study from Italy with a 22 years span,
seven patients with visceral leishmaniasis were identified, six of
them were adults, and only one child was reported (25). In the
EuroTravNet multi-center study performed by Ehehalt et al., only
dealing with patients who acquired their infection within Europe,
10 patients with visceral leishmaniasis were identified with an age
range between 1 and 79 years and the median age was 67 years.
Three of the 10 identified patients with visceral leishmaniasis
had a drug-induced immunosuppression (24). However, a study
performed in a children’s hospital in Tehran has shown that the
mean age of the 34 reported children suffering from visceral
leishmaniasis was 26.9months with an age range of 6–92months,
more than 90% were under the age of 5 years (1). Obviously, if
visceral leishmaniasis occurs in childhood, it affects especially
children younger than 5 years. The children reported in our case
report were under the age of 5 years, and the child reported in the
study of Calderaro et al. (25) was 2 years old.
In both patients, we decided to extend the therapy with lipo-
somal amphotericin B up to 10 days. According to the current
German guidelines, Leishmania acquired in the so-called “Old
World” (Africa, Europe, Asia) should be treated with intravenous
liposomal Amphotericin B at days 1–4 and at day 10 using
3mg/kg/day, whereas Leishmania acquired in the so-called “New
World” (North and South America) should be treated with intra-
venous 3–4mg/kg/day for 10 days. As indicated by Di Martino
et al., both therapies are effective in children (10). The regional
differences in treatment intensity of Leishmaniamay be explained
in part by different studies which have shown that Leishmania
acquired in Brazil or in the Mediterranean basin may need higher
total doses of liposomal amphotericin B than Leishmania acquired
in India (31–36). However, it has been shown that short therapy
courses with the same total dose of liposomal amphotericin Bmay
be effective in Mediterranean visceral leishmaniasis as well (37).
For economic reasons, in developing countries, oral miltefosine
may be the treatment of choice because of lower costs, the possi-
bility of oral treatment, and effectiveness (12). According to the
current German guidelines, therapy with miltefosine is allowed
in children3 years of age. 1.5–2.5mg/kg/day miltefosine should
be taken for 28 days. Because of the severe and delayed course of
disease in our two children, we decided to follow the guidelines
for Leishmania acquired in the “NewWorld.”
Concluding Remarks
In conclusion, the reported cases shall illustrate the unspecificity
of presentation of a well-known disease on the one hand and
focus on specific, yet subtle bone marrow findings on the other
hand. Therefore, in pancytopenia, a thorough analysis of the bone
marrow beyond the common focus on malignancy also searching
for parasites, such as Leishmania, is important. Due to mecha-
nisms like polyclonal B cell activation, many serologic tests might
be positive leading to false conclusions yet early initiation of a
Leishmania serology when pancytopenia is present might help to
accelerate establishing a diagnosis.
Leishmaniasis is to be included in the diagnostic considerations
in patients presenting with persistent pancytopenia, and a positive
travel history to endemic areas, as an effective therapy of this
potentially life-threatening disease is available.
Patient Consent
Family of patient A was informed and agreed upon publishing the
data; family of patient B was lost of follow-up and therefore no
consent could be obtained.
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